Roth Capital Has Negative Outlook for REVB FY2028 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Roth Capital cut their FY2028 earnings per share estimates for shares of Revelation Biosciences in a report issued on Thursday, June 5th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $0.84 per share for the year, down from their prior forecast of $1.00. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($49.33) per share.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($2.11) EPS for the quarter, beating the consensus estimate of ($6.88) by $4.77.

Separately, Wall Street Zen lowered Revelation Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd.

Revelation Biosciences Trading Down 2.9%

Shares of Revelation Biosciences stock opened at $0.84 on Monday. The firm has a market capitalization of $809,374.40, a PE ratio of 0.00 and a beta of -0.09. The business’s 50-day moving average price is $2.58 and its 200-day moving average price is $4.50. Revelation Biosciences has a 12 month low of $0.77 and a 12 month high of $60.80.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.